SYNCOPE and Cymbalta

PatientsVille

Find and Compare Side Effects

SYNCOPE Symptoms and Causes

Fainting is a temporary loss of consciousness. If you're about to faint, you'll feel dizzy, lightheaded, or nauseous. Your field of vision may "white out" or "black out." Your skin may be cold and clammy. You lose muscle control at the same time, and may fall down.

Fainting usually happens when your blood pressure drops suddenly, causing a decrease in blood flow to your brain. It is more common in older people. Some causes of fainting include

Heat or dehydration

Emotional distress

Standing up too quickly

Certain medicines

Drop in blood sugar

Heart problems

When someone faints, make sure that the airway is clear and check for breathing. The person should stay lying down for 10-15 minutes. Most people recover completely. Fainting is usually nothing to worry about, but it can sometimes be a sign of a serious problem. If you faint, it's important to see your health care provider and find out why it happened.

SYNCOPE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Primary Outcome 1. Time to ECG (objective) diagnosis of Syncope; 1. Time to ECG directed therapy. 2. Time to introduction of empiric therapy. 3. Time to first post induction Syncope. 4. Cost effectiveness analysis.

The primary outcome measure will be the proportion of patients having at least one Syncope recurrence.; A secondary outcome will be the time between the first and second Syncope recurrences.; A secondary outcome will be the frequency of syncopal spells.; A secondary outcome is the number, duration, and severity of presyncopal spells (as measured with the Calgary PreSyncope Scale(19)).; A secondary outcomes will be quality of life as measured by the EQ-5D and the ISQL.

The primary outcome measure will be the proportion of patients having at least one Syncope recurrence.; A secondary outcome will be the time between the first and second Syncope recurrences.; A secondary outcome will be the frequency of syncopal spells.; A secondary outcome is the number, duration, and severity of presyncopal spells (as measured with the Calgary PreSyncope Scale); A secondary outcomes will be quality of life as measured by the EQ-5D and the ISQL.

Other: Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer

Outcome Measures:

To assess the prevalence of PE in a large series of consecutive patients presenting with the first episode of Syncope; To assess the prevalence of pulmonary embolism in patients with apparently unexplained Syncope

The primary outcome measure will be a composite of Major Adverse Study-Related Events (MASRE) in a 2-year observation period.; Secondary outcome measures will include total number of syncopal spells.; Secondary outcome measures will include the likelihood of a first recurrence of Syncope.; Secondary outcome measures will include the physical trauma due to Syncope.; Secondary outcome measures will include quality of life of the participants.

Recording of symptomatic or life threatening arrhythmia event; Occurrence of silent (asymptomatic) arrhythmia event; 1. Verification of patient self assessment based on the Quality of Life questionnaire and EHRA scale against evidence of cardiac arrhythmia occurrence

Time to Final Emergency Department Disposition; Time to therapeutic intervention; Time to clinical procedure; Number and Type of other imaging studies; Information Content provided by Point-of-Care Ultrasound; Number and type of laboratory studies; Number of and time to consultant services

Accumulated incidence of presyncopal and syncopal reactions during blood donation, while still at the blood donation whole and within 48 hours of the blood donation, that required the donor to be placed in a 'Trendelenburg' position; daily activities; presyncopal and syncopal reactions of all donors; presyncopal and syncopal reactions in the population of young donors (in schools); presyncopal or syncopal reactions influence on subsequent blood donation; Recurrence of presyncopal or syncopal reactions; Explanatory variables of presyncopal and syncopal reactions; subgroup analysis on collection unit characteristics; medium term impact of the donation; Restless legs syndrome

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.